Human granulocytic ehrlichiosis agent infection in a pony vaccinated with a Borrelia burgdorferi recombinant OspA vaccine and challenged by exposure to naturally infected ticks.
A pony was vaccinated with recombinant OspA vaccine (rOspA) and then exposed 3 months later to Borrelia burgdorferi-infected ticks (Ixodes scapularis) collected in Westchester County, N.Y. At 2 weeks after tick exposure, the pony developed a high fever (105 degrees F). Buffy coat smears showed that 20% of neutrophils contained ehrlichial inclusion bodies (morulae). Flunixin Meglumine (1 g daily) was given for 2 days, and the body temperature returned to normal. PCR for ehrlichial DNA was performed on blood samples for 10 consecutive days beginning when the pony was first febrile. This pony was monitored for another 3.5 months but developed no further clinical signs. The 44-kDa immunodominant human granulocytic ehrlichiosis antigen gene was amplified by PCR and cloned into a pCR2.1 vector. DNA sequence analysis of this gene showed it was only 8 bp different (99% identity) from the results reported by others (J. W. Ijdo et al., Infect. Immun. 66:3264-3269, 1998). Western blot analysis, growth inhibition assays, and repeated attempts to isolate B. burgdorferi all demonstrated the pony was protected against B. burgdorferi infection. These results highlight the potential for ticks to harbor and transmit several pathogens simultaneously, which further complicates the diagnosis and vaccination of these emerging tick-borne diseases.
Chang
Y F
YF
Department of Population Medicine and Diagnostic Science, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA. yc42@cornell.edu
McDonough
S P
SP
Chang
C F
CF
Shin
K S
KS
Yen
W
W
Divers
T
T
D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics; D000954:Antigens, Surface / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D015748:Borrelia burgdorferi Group / Q000276:immunology* / Q000302:isolation & purification; D003002:Clonixin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004269:DNA, Bacterial / Q000097:blood; D018469:Ehrlichia chaffeensis / Q000276:immunology; D016873:Ehrlichiosis / Q000276:immunology / Q000382:microbiology* / Q000517:prevention & control*; D006098:Granulocytes / Q000382:microbiology; D006736:Horses; D006801:Humans; D016056:Immunodominant Epitopes / Q000235:genetics; D007181:Inclusion Bodies, Viral; D008074:Lipoproteins; D016133:Polymerase Chain Reaction; D013987:Ticks / Q000382:microbiology; D014614:Vaccines, Synthetic / Q000276:immunology*
D000942:Antigens, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D004269:DNA, Bacterial; D016056:Immunodominant Epitopes; D008074:Lipoproteins; C072045:OspA protein; D014614:Vaccines, Synthetic; C014558:flunixin meglumine; D003002:Clonixin